Table 2 Secondary outcomes
Outcomes | Slow infusion (n = 33) | Rapid infusion (n = 31) | Absolute difference/risk reduction (95%CI) | P value |
|---|---|---|---|---|
Hemodynamic outcomes | ||||
Change in plasma volume over time, min ml/kg | 866 ± 341 | 1226 ± 419 | 360 (169 to 550) | P < 0.001 |
TER, %/h | 5.3 ± 3.1 | 5.4 ± 3.0 | 0.1 (− 1.6 to 1.5) | P = 0.931 |
ΔHR, beats/min | 0 ± 12 | 1 ± 10 | 1 (− 7 to 4) | P = 0.665 |
ΔScvO2, % | 1 ± 5 | 2 ± 9 | 1 (− 3 to 5) | P = 0.682 |
ΔHct, % | − 4 ± 2 | − 4 ± 2 | 0 (− 1to 1) | P = 0.912 |
ΔMAP, mmHg | 4 ± 12 | 5 ± 13 | 1 (− 7 to 6) | P = 0.830 |
ΔCVP, cmH2O | 2 ± 3 | 1 ± 3 | 1 (− 3 to 1) | P = 0.164 |
ΔAlbumin, g/l | 4.9 ± 1.6 | 3.8 ± 1.4 | 1.1 (0 to 2) | P = 0.017 |
ΔLactate, mmol/l | − 0.4 ± 0.8 | − 0.3 ± 1.2 | 0.1 (− 0.4 to 0.6) | P = 0.565 |
Postoperative complications | ||||
Postoperative complications, number | 8 | 6 | 2 (−2.2 to 0.5) | P = 0.765 |
Glycocalyx components and hormones | ||||
ΔHyaloronan, ng/mL | − 2.6 (− 29.7 to 19.1) | 2.8 (− 26.0 to 51.0) | 16.6 (− 52.8 to 19.6) | P = 0.461 |
ΔSyndecan-1, ng/mL | 31.1 (− 0.3 to 49.3) | − 1.6 (− 17.0 to 64.4) | 2.9 (− 39.1 to 44.9) | P = 0.160 |
ΔGlypican-4, ng/mL | 1.2 ± 5.8 | − 2.5 ± 7.9 | 3.6 (0 to 7.3) | P = 0.048 |
ΔCopeptin, pmol/l | − 73.9 (− 140.8 to 26.9) | − 59.3 (− 150.1 to 39.5) | 20.6 (− 40.3 to 81.6) | P = 0.785 |
ΔRenin, mU/l | − 14.3 (− 48.0 to − 5.3) | − 29.9 (− 82.8 to − 7.6) | 27.4 (− 6.2 to 60.9) | P = 0.186 |
ΔMR-proANP, pmol/l | 20.6 (10.5 to 33.2) | 47.8 (31.8 to 71.8) | − 25.3 (− 40.0 to − 10.7) | P < 0.001 |